Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
eLife · 2024
DOI: 10.7554/elife.96992 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Phaedra C Ghazi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Sciences, University of Utah, Salt Lake City, United States. Hauptthemen laut MEDLINE: Autophagy-Related Protein-1 Homolog, Cell Proliferation, Intracellular Signaling Peptides and Proteins, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent U.S. Food and Drug Administration approval of covalent inhibitors of KRAS G12C such as sotorasib or adagrasib, KRAS oncoproteins are important pharmacological targets in non-small cell lung cancer (NSCLC). However, not all KRAS G12C -driven NSCLCs respond to these inhibitors, and the emergence of drug resistance in those patients who do respond can be rapid and pleiotropic. Hence, based on a backbone of covalent inhibition of KRAS G12C , efforts are underway to develop effective combination therapies. Here, we report that the inhibition of KRAS G12C signaling increases autophagy in KRAS G12C -expressing lung cancer cells. Moreover, the combination of DCC-3116, a selective ULK1/2 inhibitor, plus sotorasib displays cooperative/synergistic suppression of human KRAS G12C -driven lung cancer cell proliferation in vitro and superior tumor control in vivo. Additionally, in genetically engineered mouse models of KRAS G12C -driven NSCLC, inhibition of either KRAS G12C or ULK1/2 decreases tumor burden and increases mouse survival. Consequently, these data suggest that ULK1/2-mediated autophagy is a pharmacologically actionable cytoprotective stress response to inhibition of KRAS G12C in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncological Sciences, University of Utah, Salt Lake City, United States.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, United States.
- Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, United States.
- Deciphera Pharmaceuticals, St. Lawrence, United States.
- Department of Pathology, University of Utah, Salt Lake City, United States.
- Department of Internal Medicine, Division of Medical Oncology, University of Utah, Salt Lake City, United States.
ORCID-Profile: Phaedra C Ghazi, Guillermina Lozano, Eric L Snyder, Conan G Kinsey, Martin McMahon
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- Huntsman Cancer Foundation
- Huntsman Cancer Institute, University of Utah
- V Foundation for Cancer Research
Zitieren
APA
Ghazi, P. C., O'Toole, K. T., Srinivas Boggaram, S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., Snyder, E. L., Kinsey, C. G., & McMahon, M. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. https://doi.org/10.7554/elife.96992
Vancouver
Ghazi PC, O'Toole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, et al. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 2024. doi:10.7554/elife.96992
BibTeX
@article{Ghazi2024,
author = {Ghazi, Phaedra C and O'Toole, Kayla T and Srinivas Boggaram, Sanjana and Scherzer, Michael T and Silvis, Mark R and Zhang, Yun and Bogdan, Madhumita and Smith, Bryan D and Lozano, Guillermina and Flynn, Daniel L and Snyder, Eric L and Kinsey, Conan G and McMahon, Martin},
title = {Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.96992}
}
EUVIMED